Related Experiment Videos
ADL-2-1294 (Adolor)
1editor@greyowltutor.com
Idrugs : the Investigational Drugs Journal
|July 28, 2005
Summary
Adolor is developing topical and ophthalmic formulations of loperamide (ADL-2-1294) for inflammatory pain and pruritus. Clinical trials are ongoing for burns, wounds, and eye conditions, with promising preclinical results.
Area of Science:
- Pharmacology
- Dermatology
- Ophthalmology
Background:
- Loperamide (ADL-2-1294), an antidiarrheal compound, acts as a peripheral opiate receptor agonist.
- Adolor is exploring novel topical and ophthalmic formulations of loperamide.
Purpose of the Study:
- To evaluate the efficacy and safety of loperamide formulations for treating inflammatory pain and pruritus.
- To investigate loperamide's potential in conditions such as burns, wounds, and eye diseases.
Main Methods:
- Phase I and II clinical trials for topical and ophthalmic formulations.
- Preclinical studies in animal models of inflammatory pain.
- Assessment of safety, tolerance, pharmacokinetics, and topical sensitivity.
Main Results:
- Positive results from Phase I trials of the topical formulation in burn patients.
- Preclinical studies demonstrated efficacy in animal models of inflammatory pain.
- Ongoing Phase II trials for topical and ophthalmic formulations.
Conclusions:
- Loperamide (ADL-2-1294) formulations show potential for treating inflammatory pain and pruritus.
- Further clinical development is warranted for various dermatological and ophthalmological conditions.
- Licensing agreements indicate commercial interest in topical ADL-2-1294.